AstraZeneca (AZN) and Daiichi Sankyo Company Limited (DSKYF) announced that the U.S. Food and Drug Administration (FDA) has granted priority review of the supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan), jointly developed by Daiichi Sankyo and AstraZeneca.   Enhertu is a HER2-directed antibody drug conjugate (ADC) designed to treat adult patients in the U.S. with unresectable or metastatic HER2-positive breast cancer. These patients include individuals who have received a prior anti-HER2-based regimen.  Daiichi Sankyo is engaged in the research, development, manufacture, and sale of pharmaceuticals, while AstraZeneca is a British-Swedish multinational pharmaceutical and biotechnology company.    The FDA grants Priority Review to medicines that potentially provide advanced treatments in the absence of alternatives.
https://www.tipranks.com/news/astrazeneca-fda-priority-review-for-enhertu-could-boost-stock?utm_source=advfn.com&utm_medium=referral
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Apr 2022 bis Mai 2022 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Mai 2021 bis Mai 2022 Click Here for more AstraZeneca Charts.